Recruitment and Retention Strategies for the Diabetes RElated to Acute Pancreatitis and Its Mechanisms Study: From the Type 1 Diabetes in Acute Pancreatitis Consortium
- PMID: 36206465
- PMCID: PMC9555856
- DOI: 10.1097/MPA.0000000000002072
Recruitment and Retention Strategies for the Diabetes RElated to Acute Pancreatitis and Its Mechanisms Study: From the Type 1 Diabetes in Acute Pancreatitis Consortium
Abstract
Recruitment and retention of patients with acute pancreatitis (AP) in clinical studies can be challenging. While some obstacles are similar to other clinical conditions, some are unique to AP. Identifying potential barriers early and developing targeted solutions can help optimize recruitment and retention in AP studies. Such pre-emptive and detailed planning can help prospective, longitudinal studies focus on exocrine and endocrine complications of AP in accurately measuring outcomes. This article highlights the challenges in recruitment and retention strategies in AP studies and reviews available resources to create opportunities to address them. We describe the multifaceted approach used by the Recruitment and Retention Committee of the Type 1 Diabetes in Acute Pancreatitis Consortium, which builds upon earlier experiences to develop a recruitment and retention plan for the DREAM (Diabetes RElated to Acute pancreatitis and its Mechanisms) study.
Copyright © 2022 Written work prepared by employees of the Federal Government as part of their official duties is, under the U.S. Copyright Act, a “work of the United States Government” for which copyright protection under Title 17 of the United States Code is not available. As such, copyright does not extend to the contributions of employees of the Federal Government.
Conflict of interest statement
E.A. is part of advisory board for Nestle. M.D.B. receives research support from Viacyte and Dexcom and is part of advisory board for Insulet. AC is part of advisory board for GSK and expert opinion for Guidepoint. P.J.L. is part of advisory board for AbbVie. G.I.P. receives research support from AbbVie, has consulting activities with Olympus and Nestle, and receives equity with Ariel Precision Medicine. The other authors declare no conflict of interest.
Figures


References
-
- Das SL, Singh PP, Phillips AR, et al. Newly diagnosed diabetes mellitus after acute pancreatitis: a systematic review and meta-analysis. Gut. 2014;63:818–831. - PubMed
-
- Shen HN, Yang CC, Chang YH, et al. Risk of diabetes mellitus after first-attack acute pancreatitis: A national population-based study. Am J Gastroenterol. 2015;110:1698–1706. - PubMed
Publication types
MeSH terms
Grants and funding
- KL2 TR002002/TR/NCATS NIH HHS/United States
- U01 DK127403/DK/NIDDK NIH HHS/United States
- U01 DK127392/DK/NIDDK NIH HHS/United States
- U01 DK127367/DK/NIDDK NIH HHS/United States
- U01 DK127395/DK/NIDDK NIH HHS/United States
- U01 DK127388/DK/NIDDK NIH HHS/United States
- U01 DK127377/DK/NIDDK NIH HHS/United States
- U01 DK127382/DK/NIDDK NIH HHS/United States
- U01 DK127400/DK/NIDDK NIH HHS/United States
- U01 DK127378/DK/NIDDK NIH HHS/United States
- U01 DK127404/DK/NIDDK NIH HHS/United States
- U01 DK127384/DK/NIDDK NIH HHS/United States